Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial.
Los artículos de esta sección se muestran en inglés.
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Trade News, 2026-09-30 resume el mercado: Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial. Fuente primaria: original en Nasdaq Market Structure (nasdaq.com).